Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 16

Small Airways Disease, Biomarkers and COPD: Where are We?

Authors Chukowry PS, Spittle DA, Turner AM

Received 4 September 2020

Accepted for publication 11 December 2020

Published 18 February 2021 Volume 2021:16 Pages 351—365

DOI https://doi.org/10.2147/COPD.S280157

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Priyamvada S Chukowry,1 Daniella A Spittle,2 Alice M Turner3

1Respiratory Research Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 2Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK; 3Institute for Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK

Correspondence: Alice M Turner
Institute for Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK
Tel +44 0121 3713885
; +44 07825683519
Email A.M.Turner@bham.ac.uk

Abstract: The response to treatment and progression of Chronic Obstructive Pulmonary Disease (COPD) varies significantly. Small airways disease (SAD) is being increasingly recognized as a key pathological feature of COPD. Studies have brought forward pathological evidence of small airway damage preceding the development of emphysema and the detection of obstruction using traditional spirometry. In recent years, there has been a renewed interest in the early detection of SAD and this has brought along an increased demand for physiological tests able to identify and quantify SAD. Early detection of SAD allows early targeted therapy and this suggests the potential for altering the course of disease. The aim of this article is to review the evidence available on the physiological testing of small airways. The first half will focus on the role of lung function tests such as maximum mid-expiratory flow, impulse oscillometry and lung clearance index in detecting and quantifying SAD. The role of Computed Tomography (CT) as a radiological biomarker will be discussed as well as the potential of recent CT analysis software to differentiate normal aging of the lungs to pathology. The evidence behind SAD biomarkers sourced from blood as well as biomarkers sourced from sputum and broncho-alveolar lavage (BAL) will be reviewed. This paper focuses on CC-16, sRAGE, PAI-1, MMP-9 and MMP-12.

Keywords: spirometry, targeted treatment, normal aging, pathological process

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]